Released Sep 2, 2026, after the close
10-Q filed Sep 2, 2026, 64 days after period end · 0001193125-26-380191
On September 2, 2026, Scribe Therapeutics Inc. (the "Company") announced its financial results for the quarter ended June 30, 2026 and provided a business update.
The release| Metric | Q2 2026 | Q2 2025 |
|---|---|---|
| Revenue | $1.92M | $4.90M |
| Net Income | -$6.48M | -$9.90M |
| EPS Diluted | -$2.62 | -$4.08 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Scribe Therapeutics, Inc. · CIK 1853921 · Engraved from SEC EDGAR
Scribe initiated the first-in-human Phase 1 trial of STX-1150 in Australia during mid-2026.¶2¶3¶4
Scribe received approximately $25.7 million in combined non-dilutive CIRM grants for STX-1200 and STX-1400.¶2¶5¶6¶7
Scribe completed its upsized initial public offering and concurrent private placement to Sanofi, generating approximately $155.5 million in aggregate gross proceeds.¶2¶8¶9¶10
For the three months ended June 30, 2026, collaboration revenue was $1.9 million and net loss was $6.5 million, or $2.62 per basic and diluted share.¶11¶12¶13